List of Excipients in Branded Drug NEXIUM 24HR

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Haleon US Holdings LLC	NEXIUM 24HR	esomeprazole magnesium	0573-2450	D&C RED NO. 28
Haleon US Holdings LLC	NEXIUM 24HR	esomeprazole magnesium	0573-2450	FD&C BLUE NO. 1
Haleon US Holdings LLC	NEXIUM 24HR	esomeprazole magnesium	0573-2450	FD&C RED NO. 40

NEXIUM 24HR Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

NEXIUM 24HR is an OTC delayed-release esomeprazole magnesium product whose commercial performance depends on reliable enteric protection, dose uniformity, moisture control, and consumer-friendly packaging. The principal excipient opportunity is not a new active ingredient. It is an improved oral delivery platform that can preserve esomeprazole through the stomach, release it in the intestine, and support lower-cost generic or private-label manufacturing.

What is NEXIUM 24HR and how is it formulated?

NEXIUM 24HR contains esomeprazole magnesium, equivalent to 20 mg of esomeprazole, in a delayed-release capsule. The product is indicated for the treatment of frequent heartburn, defined on the consumer label as heartburn occurring two or more days per week. The labeled regimen is one capsule daily for 14 consecutive days, with effects continuing after several days of treatment rather than providing immediate relief.[1]

The dosage form uses enteric-coated pellets or granules inside a hard gelatin capsule. This architecture addresses the principal technical problem with proton-pump inhibitors: esomeprazole is acid-labile and can degrade in the stomach before reaching its site of absorption.

Core excipient functions

Formulation component	Primary function	Commercial relevance
Sugar spheres	Inert pellet substrate	Supports layered multiparticulate manufacture
Hypromellose	Binder, film former and protective coating material	Enables uniform drug layering and coating
Methacrylic acid copolymer	Enteric polymer	Controls resistance to gastric acid and intestinal release
Triethyl citrate	Plasticizer	Improves flexibility and reduces cracking in enteric films
Talc	Anti-tacking and coating aid	Supports processability during fluid-bed coating
Polysorbate 80	Wetting or dispersion aid	Helps maintain coating and drug-layer uniformity
Crospovidone	Disintegrant or release-support excipient	Can assist dispersion after capsule opening
Magnesium stearate	Lubricant	Supports capsule and pellet manufacturing
Magnesium oxide	Alkalizing or stabilizing excipient, where used in the applicable product configuration	May support microenvironmental pH control
Gelatin	Capsule shell	Provides the immediate container for the delayed-release pellet system
Colorants and titanium dioxide	Product identification and opacity	Supports brand recognition and light protection

The exact composition can vary by market, product presentation, and manufacturing site. Commercial assessments should use the current FDA-approved labeling and the applicable product-specific inactive-ingredient record rather than assume that every NEXIUM 24HR SKU uses an identical formula.[1,2]

Which excipients are technically critical in NEXIUM 24HR?

The enteric polymer is the highest-value excipient in the formulation. It determines whether the product remains intact during gastric transit and releases esomeprazole at the intended intestinal pH. Methacrylic acid copolymers are commercially established for this purpose, but polymer grade, particle size, neutralization behavior, plasticizer ratio, coating weight gain, and curing conditions can materially change dissolution performance.

Enteric polymer selection

A generic or private-label developer can evaluate:

• Methacrylic acid-ethyl acrylate copolymers
• Methacrylic acid-methyl methacrylate copolymers
• Cellulose acetate phthalate
• Hypromellose phthalate
• Hypromellose acetate succinate
• Polyvinyl acetate phthalate

The commercial choice must preserve acid resistance and match the reference product’s dissolution profile. A technically acceptable alternative polymer may still create regulatory risk if it changes release timing, pellet integrity, impurity formation, or food-effect behavior.

Plasticizer and coating performance

Triethyl citrate is a conventional plasticizer for enteric coatings. Alternative plasticizers such as acetyl tributyl citrate, diethyl phthalate, polyethylene glycol, or propylene glycol may offer different flexibility, film permeability, processing windows, and regulatory profiles.

The main development opportunity is a lower coating weight that provides equivalent gastric protection. Lower polymer use can reduce material cost, coating time, batch-cycle duration, and capsule fill weight. The risk is a narrower process window, particularly under high humidity or during long-term storage.

Alkaline microenvironment control

Esomeprazole stability can improve when the drug is protected from acidic microenvironments. Alkalizing excipients, including selected magnesium salts or carbonate-based materials, can be assessed as part of the drug-layer or subcoating system. Their use requires control of:

• Local pH around the drug particles
• Water activity
• Magnesium or carbonate content
• Interaction with the enteric polymer
• Dissolution after intestinal transfer
• Formation of degradation products

An alkaline excipient can improve chemical stability but may increase hygroscopicity, alter pellet density, or affect coating adhesion. It should be evaluated as a system component rather than as a simple one-for-one replacement.

What excipient strategy best supports generic NEXIUM 24HR?

The strongest generic strategy is a multiparticulate capsule with a functionally equivalent enteric-coated pellet system. A conventional immediate-release capsule is unsuitable because it would expose esomeprazole to gastric acid and would not replicate the reference product’s delayed-release performance.

Reference-product matching

A development program should characterize:

1. Pellet size distribution
2. Drug-layer thickness
3. Subcoating composition
4. Enteric polymer type and level
5. Plasticizer concentration
6. Coating weight gain
7. Acid-stage dissolution
8. Buffer-stage release
9. Assay and content uniformity
10. Degradation products under accelerated storage

The formulation need not use the same excipients in the same quantities. It must demonstrate equivalent performance under the applicable FDA pathway. FDA’s product-specific guidance for delayed-release esomeprazole magnesium products is relevant to dissolution and bioequivalence planning.[3]

Multiparticulate advantages

Pellets distribute the dose through the gastrointestinal tract more broadly than a single monolithic tablet. They also support:

• Consistent enteric protection
• Reduced sensitivity to localized coating defects
• Capsule opening for selected administration scenarios
• Flexible fill weights
• Different capsule sizes and pack counts
• Potential use in sprinkle or sachet presentations, subject to regulatory support

The principal disadvantage is manufacturing complexity. Drug layering, subcoating, enteric coating, curing, drying, and capsule filling require more equipment and in-process control than standard tablet compression.

What formulation innovations create commercial opportunities?

The most credible commercial opportunities are improvements in convenience, stability, manufacturing economics, and channel flexibility.

Lower-cost enteric coating systems

A developer can pursue a coating package that uses less polymer and shorter processing time while maintaining the reference dissolution profile. The opportunity is strongest for high-volume store-brand and retailer programs where a small reduction in unit cost has a material effect across 14-, 28-, and 42-count packages.

Potential development targets include:

• Higher-solids aqueous coating systems
• Optimized plasticizer ratios
• Reduced talc loading
• Continuous fluid-bed coating
• Improved curing conditions
• Lower-temperature film formation
• Polymer blends with wider process windows

Cost savings must be measured against yield loss, coating defects, stability failures, and batch-release testing.

Moisture-protective packaging

Moisture is a major risk for enteric-coated PPI pellets. Packaging improvements can protect potency and dissolution without changing the active formulation.

Commercial options include:

• High-barrier blister packs
• Desiccant-containing bottles
• Induction-sealed HDPE containers
• Unit-dose foil pouches
• Child-resistant unit-dose packaging
• Smaller headspace bottles
• Improved closure systems

A better package may support longer shelf life, lower impurity growth, and fewer dissolution failures. Packaging changes can also support e-commerce distribution, where products experience wider temperature and humidity excursions than controlled retail storage.

Sprinkle and single-dose formats

A capsule that can be opened and sprinkled over soft food may expand use among consumers who have difficulty swallowing. A single-dose sachet or stick-pack could improve portability and support travel, workplace, and subscription channels.

These formats carry technical constraints. The enteric-coated pellets must remain intact during handling, must not be crushed, and must retain their release profile after exposure to the selected food vehicle. Labeling must clearly state how the contents are administered.

Chewable or orally disintegrating presentations

A chewable or orally disintegrating esomeprazole product could compete on convenience, but the formulation challenge is substantial. The active pellets must remain protected from saliva and gastric acid while the dosage form disperses rapidly in the mouth.

Possible approaches include:

• Enteric-coated microgranules in an orally disintegrating matrix
• Taste-masked pellets
• Low-moisture direct compression
• Rapidly dispersible granules
• Effervescent or buffered systems

The sensory profile is a commercial constraint. Esomeprazole and its stabilizing excipients can produce bitterness, chalkiness, or alkaline taste. Taste masking may require additional polymers, lipid coatings, ion-exchange systems, or sweetener combinations.

What regulatory status does NEXIUM 24HR have?

NEXIUM 24HR is an FDA-approved OTC drug product rather than a product marketed solely under the OTC monograph system. FDA approved the OTC switch for Nexium 24HR in 2014. The product is associated with an approved new drug application and is subject to FDA labeling, quality, manufacturing, and postmarketing requirements.[1,4]

The OTC label limits consumer use to a 14-day course. Consumers are directed to seek medical advice for persistent or recurrent symptoms. That positioning creates a regulatory boundary for commercial extensions: a new dosage form, strength, indication, or treatment duration may require a new regulatory submission or supplemental approval.

FDA pathway considerations

A generic or store-brand developer may evaluate an abbreviated new drug application where the reference product and regulatory pathway support that approach. The key issues are:

• Reference listed drug selection
• Strength and dosage-form equivalence
• Delayed-release performance
• Bioequivalence
• Inactive-ingredient safety
• Labeling conformity
• Manufacturing-site qualification
• Stability and container-closure performance

The use of different excipients is generally possible, but the applicant must demonstrate that the differences do not affect safety, efficacy, bioavailability, or product performance.

What patents protect NEXIUM 24HR and when does exclusivity end?

The major historical patent estate for esomeprazole covered the active compound and prescription formulations. Those protections are distinct from the current commercial value of NEXIUM 24HR as an OTC branded product.

For a current excipient and generic strategy, the relevant questions are:

• Whether any active patent is listed for the specific OTC reference product
• Whether a formulation patent covers the delayed-release pellet architecture
• Whether method-of-use claims remain enforceable
• Whether a third party owns patents on a particular coating composition
• Whether the proposed generic design avoids those claims

The FDA Orange Book is the primary source for checking listed patents and exclusivity associated with an approved drug application. Patent status should be assessed by product, application number, jurisdiction, and expiration calculation. A historical esomeprazole patent should not be treated as a current barrier without confirming its term, pediatric adjustments, terminal disclaimers, and claim scope.[5]

Are biosimilars a risk for NEXIUM 24HR?

No. Esomeprazole is a chemically synthesized small molecule. NEXIUM 24HR faces generic, authorized-generic, private-label, and branded OTC competition, not biosimilar competition. The relevant competitive threats are formulation equivalence, retail placement, price, consumer recognition, and regulatory speed.

How strong is the NEXIUM 24HR formulation estate?

The formulation is technically defensible but not necessarily commercially exclusive. Enteric-coated esomeprazole pellets use well-established pharmaceutical technologies. The strongest protection for a developer would likely come from a specific combination of:

• Drug-layer composition
• Alkaline stabilizer level
• Subcoating structure
• Enteric-polymer blend
• Coating weight gain
• Dissolution profile
• Moisture-control package
• Manufacturing process parameters

Broad claims covering an enteric-coated PPI capsule may face prior-art challenges. Narrower claims directed to a defined impurity profile, accelerated-stability result, coating architecture, or manufacturing process may have greater practical value if supported by comparative data.

A company should separate freedom-to-operate analysis from regulatory similarity. A formulation may be acceptable for an ANDA and still infringe a third-party process or composition patent. Conversely, a design-around may avoid patent claims but require additional clinical or bioequivalence work.

Which commercial companies can benefit from excipient innovation?

Generic manufacturers

Generic manufacturers can compete through lower-cost pellet production, faster coating cycles, and flexible packaging. The most attractive targets are retailer-branded 14-day and 28-day products, where the active ingredient is mature and consumers are price sensitive.

Excipient suppliers

Excipient suppliers can create value through:

• Pre-engineered enteric-coating systems
• Ready-to-use aqueous polymer dispersions
• Low-moisture stabilizing blends
• Taste-masking systems
• Pelletization platforms
• High-barrier packaging components
• Continuous coating equipment and process controls

A supplier that offers a validated coating platform with dissolution and stability data can reduce a generic manufacturer’s development time.

Contract development and manufacturing organizations

CDMOs with fluid-bed coating, drug layering, pellet classification, and capsule-filling capacity are positioned to support OTC launches without requiring the brand owner to build dedicated infrastructure. The critical qualification criteria are scale-up reproducibility, coating uniformity, containment, and stability performance.

Consumer-health companies

Consumer-health companies can differentiate through:

• Smaller portable packs
• Subscription-oriented multipacks
• Easy-open packaging
• Sprinkle-compatible products
• Retailer-specific packaging
• Combination heartburn portfolios
• Improved labeling and treatment-duration communication

The brand owner must avoid implying immediate relief, chronic disease treatment, or superiority unsupported by the approved label.

How does NEXIUM 24HR compare with competing OTC acid reducers?

Product category	Typical active ingredient	Release strategy	Excipient opportunity
NEXIUM 24HR	Esomeprazole	Delayed release	Enteric pellet stability and coating economics
Prilosec OTC	Omeprazole	Delayed release	Similar acid-labile PPI delivery issues
Prevacid 24HR	Lansoprazole	Delayed release	Pellet or capsule coating and taste masking
Pepcid AC	Famotidine	Generally immediate release	Tablet disintegration and taste or swallowability
Antacids	Calcium carbonate, magnesium hydroxide, or similar salts	Immediate neutralization	Compressibility, mouthfeel, and mineral compatibility
Alginate products	Alginate with antacid combinations	Physical barrier plus neutralization	Viscosity, buoyancy, and suspension stability

NEXIUM 24HR competes most directly with other delayed-release PPIs. Its excipient strategy therefore needs to support consistent release and shelf stability, while its commercial strategy must address the consumer tradeoff between longer-lasting acid suppression and the faster perceived action of antacids or H2 blockers.

What generic launch risks exist for NEXIUM 24HR?

The main generic launch risks are formulation and regulatory execution rather than biosimilar substitution.

Risk	Impact	Mitigation
Inadequate acid resistance	Premature drug release and failed dissolution	Optimize polymer, coating weight, and curing
Excessive enteric protection	Delayed or incomplete release	Conduct multi-stage dissolution testing
Moisture uptake	Degradation and capsule or coating defects	Use barrier packaging and controlled humidity
Pellet segregation	Dose variability	Control pellet size, density, and capsule filling
Impurity growth	Batch rejection or shelf-life reduction	Establish stabilizing microenvironment and packaging
Taste exposure after capsule opening	Poor consumer acceptance	Develop sprinkle instructions and taste masking
Patent or FTO issue	Launch delay or litigation	Review Orange Book and third-party patent claims
Retail price compression	Lower gross margin	Reduce coating cost and packaging complexity
OTC labeling noncompliance	Regulatory or recall exposure	Match approved indication and duration language

What licensing deals and partnerships are commercially relevant?

The most practical licensing opportunities concern formulation platforms rather than the esomeprazole molecule. Potential deal structures include:

• Nonexclusive licenses for enteric-coating technology
• Supply agreements for functionalized methacrylic acid copolymers
• CDMO agreements for pellet manufacture
• Co-development of sprinkle or orally disintegrating products
• Packaging licenses for high-barrier unit-dose formats
• Retailer-specific private-label manufacturing agreements

A licensor should protect process know-how, coating specifications, analytical methods, and scale-up data separately from patent rights. A formulation patent without manufacturing support may have limited commercial value, while a validated platform with reproducible dissolution data can support milestone payments, minimum-volume commitments, and long-term supply contracts.

Key Takeaways

• NEXIUM 24HR is a 20 mg delayed-release esomeprazole magnesium OTC capsule.
• The commercial core is an enteric-coated multiparticulate system designed to protect esomeprazole from gastric acid.
• Enteric polymer selection, plasticizer level, coating weight, moisture control, and impurity management are the highest-value excipient variables.
• Generic and private-label opportunities are strongest in lower-cost pellet manufacturing, improved barrier packaging, portable formats, and sprinkle-compatible presentations.
• NEXIUM 24HR has generic competition risk, not biosimilar risk.
• The FDA Orange Book and current approved labeling should control any patent, exclusivity, or reference-product assessment.
• The most defensible new IP is likely to be narrow and data-driven, covering a specific coating architecture, stability profile, impurity control system, or manufacturing process.
• Excipient suppliers and CDMOs can capture value by offering validated enteric-coating platforms rather than commodity raw materials alone.

FAQs About NEXIUM 24HR Excipients and Commercial Strategy

Can NEXIUM 24HR be reformulated as an immediate-release capsule?

No. Immediate release would expose esomeprazole to gastric acid and would not reproduce the delayed-release function of the reference product.

What is the most important excipient in NEXIUM 24HR?

The enteric polymer is the most important functional excipient because it controls gastric resistance and intestinal release.

Can a generic manufacturer use different excipients from NEXIUM 24HR?

Yes, provided the proposed product meets applicable safety, bioequivalence, dissolution, stability, and labeling requirements.

Is a chewable esomeprazole product commercially feasible?

Yes, but it requires protection of the acid-labile drug during oral administration and gastric transit, together with effective taste masking.

Does NEXIUM 24HR have biosimilar competition?

No. Esomeprazole is a small-molecule drug, so competition comes from generics, private-label products, authorized generics, and other OTC acid-reduction products.

References

1. U.S. Food and Drug Administration. (2023). NEXIUM 24HR: Esomeprazole magnesium delayed-release capsules, 20 mg, prescribing information and consumer labeling.
2. National Library of Medicine. (2024). DailyMed: NEXIUM 24HR esomeprazole magnesium delayed-release capsule.
3. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development: Esomeprazole magnesium delayed-release capsules.
4. U.S. Food and Drug Administration. (2014). FDA approves first over-the-counter proton pump inhibitor for frequent heartburn.
5. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.